Leveraging melanocortin pathways to treat glomerular diseases

Advances in Chronic Kidney Disease

Volumn 21, Issue 2, 2014, Pages 134-151

  Gong, Rujun ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Adrenocorticotropic hormone; Glomerulopathy; Melanocortin; Nephrotic syndrome; Podocyte

Indexed keywords

ALPHA INTERMEDIN DERIVATIVE; MELANOCORTIN; MELANOCORTIN RECEPTOR AGONIST;

ANAPHYLAXIS; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BEHAVIOR DISORDER; CUSHINGOID SYNDROME; CYTOSKELETON; DRUG EFFICACY; DRUG SAFETY; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GLOMERULOPATHY; HUMAN; HYPERTENSION; IDIOPATHIC DISEASE; IMMUNOMODULATION; KIDNEY; KIDNEY FUNCTION; MEMBRANOUS GLOMERULONEPHRITIS; MINOR AFFECTIVE DISORDER; MOOD CHANGE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SLEEP DISORDER; TARGET ORGAN;

ADRENOCORTICOTROPIC HORMONE; GLOMERULOPATHY; MELANOCORTIN; NEPHROTIC SYNDROME; PODOCYTE;

ADRENOCORTICOTROPIC HORMONE; ALPHA-MSH; COSYNTROPIN; ENDOTHELIAL CELLS; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HORMONES; HUMANS; KIDNEY; KIDNEY GLOMERULUS; MELANOCORTINS; MESANGIAL CELLS; NEPHROSIS, LIPOID; NEPHROTIC SYNDROME; PODOCYTES; RECEPTORS, MELANOCORTIN; SIGNAL TRANSDUCTION;

EID: 84896889779     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2013.09.004     Document Type: Review

References (118)

1. Meyers C.M., Geanacopoulos M., Holzman L.B., Salant D.J. Glomerular disease workshop. J Am Soc Nephrol 2005, 16(12):3472-3476.
2. Kher A., Kher V. Immunotherapy in renal diseases. Med Clin North Am 2012, 96(3):545-564.
3. Jennette J.C., Falk R.J. Diagnosis and management of glomerular diseases. Med Clin North Am 1997, 81(3):653-677.
4. Greenbaum L.A., Benndorf R., Smoyer W.E. Childhood nephrotic syndrome-current and future therapies. Nat Rev Nephrol 2012, 8(8):445-458.
5. Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children. Kidney Int 1981, 20(6):765-771.
6. Colattur S.N., Korbet S.M. Long-term outcome of adult onset idiopathic minimal change disease. Saudi J Kidney Dis Transpl 2000, 11(3):334-344.
7. Cattran D.C., Delmore T., Roscoe J., et al. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med 1989, 320(4):210-215.
8. Cameron J.S., Healy M.J., Adu D. The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party. Q J Med 1990, 74(274):133-156.
9. Pei Y., Cattran D., Delmore T., et al. Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry Study. Am J Med 1987, 82(5):938-944.
10. Faul C., Donnelly M., Merscher-Gomez S., et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008, 14(9):931-938.
11. Par A. Levamisole as immunostimulant in the clinical practice. Ther Hung 1983, 31(4):161-171.
12. Berg A.L., Arnadottir M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol Dial Transplant 2004, 19(5):1305-1307.
13. Berg A.L., Nilsson-Ehle P., Arnadottir M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int 1999, 56(4):1534-1543.
14. Bomback A.S., Canetta P.A., Beck L.H., Avalon R., Radhakrishnan J., Appel G.B. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am J Nephrol 2012, 36(1):58-67.
15. Bomback A.S., Tumlin J.A., Baranski J.J., et al. Treatment of resistant nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des Devel Ther 2011, 5:147-153.
16. Ponticelli C., Passerini P., Salvadori M., et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 2006, 47(2):233-240.
17. Gong R. The renaissance of corticotropin therapy in proteinuric nephropathies. Nat Rev Nephrol 2011, 8(2):122-128.
18. Gantz I., Fong T.M. The melanocortin system. Am J Physiol Endocrinol Metab 2003, 284(3):E468-E474.
19. Cone R.D. Studies on the physiological functions of the melanocortin system. Endocr Rev 2006, 27(7):736-749.
20. Hadley M.E., Haskell-Luevano C. The proopiomelanocortin system. Ann N Y Acad Sci 1999, 885:1-21.
21. Papadimitriou A., Priftis K.N. Regulation of the hypothalamic-pituitary-adrenal axis. Neuroimmunomodulation 2009, 16(5):265-271.
22. Veldhuis J.D., Iranmanesh A., Johnson M.L., Kuzarrakde G. Amplitude, but not frequency, modulation of adrenocorticotropin secretory bursts gives rise to the nyctohemeral rhythm of the corticotropic axis in man. J Clin Endocrinol Metab 1990, 71(2):452-463.
23. Krude H., Biebermann H., Luck W., et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998, 19(2):155-157.
24. Abdel-Malek Z.A. Melanocortin receptors: their functions and regulation by physiological agonists and antagonists. Cell Mol Life Sci 2001, 58(3):434-441.
25. Cone R.D., Lu D., Koppula S., et al. The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Recent Prog Horm Res 1996, 51:287-317. discussion: 318].
26. Doi K., Hu X., Yuen P.S., et al. AP214, an analogue of alpha-melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney injury and mortality. Kidney Int 2008, 73(11):1266-1274.
27. Gong R., Dworkin L.D. Adrenocorticotropin (ACTH) gel suppresses renal tubulointerstitial inflammation and injury by direct stimulation of the melanocortin 1 receptor (MC1R). J Am Soc Nephrol 2011, 22:136A.
28. Si J., Ge Y., Zhuang S., Chen S., Gong R. Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms. Kidney Int 2013, 83(4):635-646.
29. Maaser C., Kannengiesser K., Specht C., et al. Crucial role of the melanocortin receptor MC1R in experimental colitis. Gut 2006, 55(10):1415-1422.
30. Humphreys M.H. Cardiovascular and renal actions of melanocyte-stimulating hormone peptides. Curr Opin Nephrol Hypertens 2007, 16(1):32-38.
31. Arneil G.C., Wilson H.E. A.C.T.H. in nephrosis. Arch Dis Child 1953, 28(141):372-380.
32. Lindskog A., Ebefors K., Johansson M.E., et al. Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol 2010, 21(8):1290-1298.
33. Gong R., Dworkin L.D. ACTH(Acthar Gel) prevents proteinuria and renal injury in the remnant kidney: Evidence for direct podocyte protection. J Am Soc Nephrol 2010, 21:548A.
34. Lee S.Y., Jo S.K., Cho W.Y., Kim H.K., Won N.H. The effect of alpha-melanocyte-stimulating hormone on renal tubular cell apoptosis and tubulointerstitial fibrosis in cyclosporine A nephrotoxicity. Transplantation 2004, 78(12):1756-1764.
35. Li C., Shi Y., Wang W., et al. alpha-MSH prevents impairment in renal function and dysregulation of AQPs and Na-K-ATPase in rats with bilateral ureteral obstruction. Am J Physiol Renal Physiol 2006, 290(2):F384-F396.
36. Ni X.P., Bhargava A., Pearce D., Humphreys M.H. Modulation by dietary sodium intake of melanocortin 3 receptor mRNA and protein abundance in the rat kidney. Am J Physiol Regul Integr Comp Physiol 2006, 290(3):R560-R567.
37. Lee Y.S., Park J.J., Chung K.Y. Change of melanocortin receptor expression in rat kidney ischemia-reperfusion injury. Transplant Proc 2008, 40(7):2142-2144.
38. Chhajlani V. Distribution of cDNA for melanocortin receptor subtypes in human tissues. Biochem Mol Biol Int 1996, 38(1):73-80.
39. Sanchez E., Rubio V.C., Cerda-Reverter J.M. Characterization of the sea bass melanocortin 5 receptor: a putative role in hepatic lipid metabolism. J Exp Biol 2009, 212(Pt 23):3901-3910.
40. Elvin J., Jonsson A.L., Buvall L.M., et al. The melanocortin receptor 1: A potential target for therapeutical drugs in nephrotic syndrome. JAm Soc Nephrol 2012, 23:825A.
41. Yamada S., Bandai S., Masutani K., et al. Focal segmental glomerulosclerosis in a patient with isolated ACTH deficiency and reversible hypothyroidism. Clin Exp Nephrol 2010, 14(2):168-172.
42. Schwyzer R. ACTH: a short introductory review. Ann N Y Acad Sci 1977, 297:3-26.
43. Gettig J., Cummings J.P., Matuszewski K. H.p. Acthar gel and cosyntropin review: clinical and financial implications. P T 2009, 34(5):250-257.
44. Berg AL. Plasma cortisol levels after natural ACTH1-39 and synthetic ACTH1-24 in humans. Paper presented at: National Kidney Foundation 2013 Spring Clinical Meetings; 2013; Poster218.
45. Wan L., Chen Y.H., Chang T.W. Improving pharmacokinetic properties of adrenocorticotropin by site-specific lipid modification. JPharm Sci 2003, 92(9):1882-1892.
46. Schoneshofer M., Goverde H.J. Corticotropin in human plasma. General considerations. Surv Immunol Res 1984, 3(1):55-63.
47. Jones C.T., Kendall J.Z., Ritchie J.W., et al. Adrenocorticotrophin and corticosteroid changes during dexamethasone infusion to intact and synacthen infusion to hypophysectomized foetuses. Acta Endocrinol (Copenh) 1978, 87(1):203-211.
48. Loh Y.P., Gainer H. Evidence that glycosylation of pro-opiocortin and ACTH influences their proteolysis by trypsin and blood proteases. Mol Cell Endocrinol 1980, 20(1):35-44.
49. Schwandt P. Hypothalamic control of lipid metabolism. Acta Neurochir (Wien) 1985, 75(1-4):122-124.
50. Beloff-Chain A., Billingham N., Cawthorne M.A. Stimulation of insulin secretion from mouse pancreatic islets, maintained in tissue culture, by the pituitary neurointermediate lobe of the genetically obese mouse (ob/ob). Biochem Biophys Res Commun 1980, 95(2):792-795.
51. Beloff-Chain A., Morton J., Dunmore S., Taylor G.W., Morris H.R. Evidence that the insulin secretagogue, beta-cell-tropin, is ACTH22-39. Nature 1983, 301(5897):255-258.
52. Voisey J., Carroll L., van Daal A. Melanocortins and their receptors and antagonists. Curr Drug Targets 2003, 4(7):586-597.
53. Vessillier S., Adams G., Montero-Melendez T., et al. Molecular engineering of short half-life small peptides (VIP, alphaMSH and gamma(3)MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeutics. Ann Rheum Dis 2012, 71(1):143-149.
54. Ichiyama T., Zhao H., Catania A., Furukawa S., Lipton J.M. alpha-melanocyte-stimulating hormone inhibits NF-kappaB activation and IkappaBalpha degradation in human glioma cells and in experimental brain inflammation. Exp Neurol 1999, 157(2):359-365.
55. Fabrikant J., Touloei K., Brown S.M. A review and update on melanocyte stimulating hormone therapy: afamelanotide. J Drugs Dermatol 2013, 12(7):775-779.
56. Hadley M.E., Hruby V.J., Blanchard J., et al. Discovery and development of novel melanogenic drugs. Melanotan-I and -II. Pharm Biotechnol 1998, 11:575-595.
57. Safarinejad M.R. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. J Sex Med 2008, 5(4):887-897.
58. Montero-Melendez T., Patel H.B., Seed M., et al. The melanocortin agonist AP214 exerts anti-inflammatory and proresolving properties. Am J Pathol 2011, 179(1):259-269.
59. Kievit P., Halem H., Marks D.L., et al. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes 2013, 62(2):490-497.
60. Pfaus J., Giuliano F., Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med 2007, 4(suppl 4):269-279.
61. Bomback A.S., Radhakrishnan J. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH). Discov Med 2011, 12(63):91-96.
62. Rouster-Stevens K.A., Gursahaney A., Ngai K.L., Daru J.A., Pachman L.M. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum 2008, 59(2):222-226.
63. Hofstra J.M., Brink H.S., Van de Kerkhof J.J., et al. Treatment with synthetic ACTH in patients with idiopathic membranous nephropathy and high risk for renal failure. J Am Soc Nephrol 2010, 21:680A.
64. Picardi L., Villa G., Galli F., et al. ACTH therapy in nephrotic syndrome induced by idiopathic membranous nephropathy. Clin Nephrol 2004, 62(5):403-404.
65. Beck L.H., Berg A.L., Beck D.M., et al. Treatment of idiopathic membranous nephropathy with ACTH is associated with a decline in anti-PLA2R antibody. J Am Soc Nephrol 2009, 20:306A.
66. Beck L.H., Fervenza F.C., Bomback A.S., et al. Response of anti-PLA2R to adrenocorticotropic hormone (ACTH) gel in membranous nephropathy. J Am Soc Nephrol 2011, 22:33A.
67. Hladunewich M.A., Fervenza F.C., Beck L.H., et al. A pilot study to determine dose, effectiveness and depletion of anti-PLA2R antibodies of adrenocorticotropic hormone (ACTH Acthar gel) in subjects with nephrotic syndrome and idiopathic membranous nephropathy (iMN). J Am Soc Nephrol 2012, 23:58A.
68. Cooper A., Robinson S.J., Pickard C., et al. Alpha-melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status. J Immunol 2005, 175(7):4806-4813.
69. Farnsworth EB. Studies on the influence of adrenocorticotrophin in acute nephritis, in simple nephrosis and in nephrosis with azotemia. In: Mote JR, ed. Proceedings of the First Clinical ACTH Congress. The Blakiston Company, Philadelphia, PA; 1950:297-317.
70. Piel C.F. Management of nephrosis; the use of long continued hormone therapy. Calif Med 1956, 85(3):152-156.
71. Hogan J.J., Bomback A.S., Canetta P.A., et al. Treatment of resistant primary focal segmental glomerulosclerosis (FSGS) with adrenocorticotropic hormone (ACTH) gel. J Am Soc Nephrol 2012, 23:725A.
72. Berg A.L., Dolinina J., Bakoush O. Treatment of focal segmental glomerulosclerosis with ACTH. J Am Soc Nephrol 2012, 23:941A.
73. Mundel P., Shankland S.J. Podocyte biology and response to injury. J Am Soc Nephrol 2002, 13(12):3005-3015.
74. Pippin J.W., Brinkkoetter P.T., Cormack-Aboud F.C., et al. Inducible rodent models of acquired podocyte diseases. Am J Physiol Renal Physiol 2009, 296(2):F213-F229.
75. Garcia D.L., Rennke H.G., Brenner B.M., et al. Chronic glucocorticoid therapy amplifies glomerular injury in rats with renal ablation. JClin Invest 1987, 80(3):867-874.
76. Patel A.B., Markell M.S. Use of ACTH gel in a patient with progressive nephrotic syndrome secondary to transplant glomerulopathy (TG). J Am Soc Nephrol 2012, 23:365A.
77. Symmers W.S. Thrombotic microangiopathic haemolytic anaemia (thrombotic microangiopathy). Br Med J 1952, 2(4790):897-903.
78. Berg AL, Back SE. ACTH treatment in patients with lupus nephritis. Paper presented at: National Kidney Foundation 2013 Spring Clinical Meetings; 2013; Poster217.
79. Katritch V., Cherezov V., Stevens R.C. Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol 2013, 53:531-556.
80. Herraiz C., Journe F., Abdel-Malek Z., et al. Signaling from the human melanocortin 1 receptor to ERK1 and ERK2 mitogen-activated protein kinases involves transactivation of cKIT. Mol Endocrinol 2011, 25(1):138-156.
81. Chai B., Li J.Y., Zhang W., Ammori J.B., Mulholland M.W. Melanocortin-3 receptor activates MAP kinase via PI3 kinase. Regul Pept 2007, 139(1-3):115-121.
82. Rodrigues A.R., Pignatelli D., Almeida H., Gouveia A.M. Melanocortin 5 receptor activates ERK1/2 through a PI3K-regulated signaling mechanism. Mol Cell Endocrinol 2009, 303(1-2):74-81.
83. Vongs A., Lynn N.M., Rosenblum C.I. Activation of MAP kinase by MC4-R through PI3 kinase. Regul Pept 2004, 120(1-3):113-118.
84. Murphy L.O., Blenis J. MAPK signal specificity: the right place at the right time. Trends Biochem Sci 2006, 31(5):268-275.
85. Andersen G.N., Hagglund M., Nagaeva O., et al. Quantitative measurement of the levels of melanocortin receptor subtype 1, 2, 3 and 5 and pro-opio-melanocortin peptide gene expression in subsets of human peripheral blood leucocytes. Scand J Immunol 2005, 61(3):279-284.
86. Delgado M., Ganea D. Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents. Brain Behav Immun 2008, 22(8):1146-1151.
87. Gonzalez-Rey E., Chorny A., Delgado M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev Immunol 2007, 7(1):52-63.
88. Catania A., Gatti S., Colombo G., et al. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 2004, 56(1):1-29.
89. Baeuerle P.A. IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell 1998, 95(6):729-731.
90. Gong R., Rifai A., Ge Y., et al. Hepatocyte growth factor suppresses proinflammatory NFkappaB activation through GSK3beta inactivation in renal tubular epithelial cells. J Biol Chem 2008, 283(12):7401-7410.
91. Wen A.Y., Sakamoto K.M., Miller L.S. The role of the transcription factor CREB in immune function. J Immunol 2010, 185(11):6413-6419.
92. Taylor A., Namba K. Invitro induction of CD25+ CD4+ regulatory T cells by the neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH). Immunol Cell Biol 2001, 79(4):358-367.
93. Shalhoub R.J. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 1974, 2(7880):556-560.
94. Koyama A., Fujisaki M., Kobayashi M., et al. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 1991, 40(3):453-460.
95. Scott G.A., Cassidy L. Rac1 mediates dendrite formation in response to melanocyte stimulating hormone and ultraviolet light in a murine melanoma model. J Invest Dermatol 1998, 111(2):243-250.
96. Busca R., Bertolotto C., Abbe P., et al. Inhibition of Rho is required for cAMP-induced melanoma cell differentiation. Mol Biol Cell 1998, 9(6):1367-1378.
97. Forssman O., Mulder J. Hypersensitivity to different ACTH peptides. Acta Med Scand 1973, 193(6):557-559.
98. Lee T.M., Grammer L.C., Shaughnessy M.A., Patterson R. Evaluation and management of corticotropin allergy. J Allergy Clin Immunol 1987, 79(6):964-968.
99. Reid I.R. Glucocorticoid effects on bone. J Clin Endocrinol Metab 1998, 83(6):1860-1862.
100. Minetto M., Reimondo G., Osella G., Ventura M., Angeli A., Terzolo M. Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome. Osteoporos Int 2004, 15(11):855-861.
101. Elias L.L., Huebner A., Metherell L.A., et al. Tall stature in familial glucocorticoid deficiency. Clin Endocrinol (Oxf) 2000, 53(4):423-430.
102. Zaidi M., Sun L., Robinson L.J., et al. ACTH protects against glucocorticoid-induced osteonecrosis of bone. Proc Natl Acad Sci U S A 2010, 107(19):8782-8787.
103. Lambillotte C., Gilon P., Henquin J.C. Direct glucocorticoid inhibition of insulin secretion. An invitro study of dexamethasone effects in mouse islets. J Clin Invest 1997, 99(3):414-423.
104. Ferris H.A., Kahn C.R. New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it. J Clin Invest 2012, 122(11):3854-3857.
105. Sussman K.E., Vaughan G.D. Insulin release after ACTH, glucagon and adenosine-3'-5'-phosphate (cyclic AMP) in the perfused isolated rat pancreas. Diabetes 1967, 16(7):449-454.
106. Al-Majed H.T., Jones P.M., Persaud S.J., et al. ACTH stimulates insulin secretion from MIN6 cells and primary mouse and human islets of Langerhans. J Endocrinol 2004, 180(1):155-166.
107. Ohsawa N., Kuzuya T., Tanioka T., Kanazawa Y., Ibayahsi H., Nakao K. Effect of administration of ACTH on insulin secretion in dogs. Endocrinology 1967, 81(4):925-927.
108. Tumlin J.A. Safety and efficacy of Acthar gel (ACTH) on albuminuria and progression of diabetic nephropathy in patients with nephrotic range proteinuria: A randomized prospective study. J Am Soc Nephrol 2010, 21:678A.
109. Greenfield J.R., Miller J.W., Keogh J.M., et al. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 2009, 360(1):44-52.
110. Ullian M.E. The role of corticosteroids in the regulation of vascular tone. Cardiovasc Res 1999, 41(1):55-64.
111. Frey F.J., Odermatt A., Frey B.M. Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. Curr Opin Nephrol Hypertens 2004, 13(4):451-458.
112. Dluhy R.G., Lifton R.P. Glucocorticoid-remediable aldosteronism. JClin Endocrinol Metab 1999, 84(12):4341-4344.
113. Mulatero P., Tizzani D., Viola A., et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension 2011, 58(5):797-803.
114. Sheppard J.R., Koestler T.P., Corwin S.P., et al. Experimental metastasis correlates with cyclic AMP accumulation in B16 melanoma clones. Nature 1984, 308(5959):544-547.
115. Bennett D.C., Dexter T.J., Ormerod E.J., Hart I.R. Increased experimental metastatic capacity of a murine melanoma following induction of differentiation. Cancer Res 1986, 46(7):3239-3244.
116. Williams P.F., Olsen C.M., Hayward N.K., Whiteman D.C. Melanocortin 1 receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden. Int J Cancer 2011, 129(7):1730-1740.
117. Smith K.R., Thiboutot D.M. Thematic review series: skin lipids. Sebaceous gland lipids: friend or foe?. J Lipid Res 2008, 49(2):271-281.
118. Tao Y.X. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr Rev 2010, 31(4):506-543.